Applied Therapeutics: No Money And No Good Data (NASDAQ:APLT)

Business on Wall Street in Manhattan

Pgiam/iStock via Getty Images

I covered Applied Therapeutics (NASDAQ:APLT) two and a half years ago, when they had already completed a phase 3 adult study, and were expecting an NDA for lead candidate AT-007 in Galactosemia “no later than Q3 2021.” Fast

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *